Cabaletta Bio to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ
PHILADELPHIA, April 25, 2023 (GLOBE NEWSWIRE) — Cabaletta Bio, Inc. (Nasdaq:CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that Steven Nichtberger, M.D., Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference at NASDAQ on Tuesday, May 2, 2023 at 1:30 p.m. ET in New York, NY.
Related news for (CABA)
- MoBot’s Stock Market Highlights – 08/13/25 03:00 PM
- Today’s Top Performers: MoBot’s Market Review 08/13/25 11:00 AM
- Cabaletta Bio Announces Proposed Public Offering of Securities
- Cabaletta Bio Announces Pricing of Public Offering of Securities
- Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress